Your browser is no longer supported. Please, upgrade your browser.
Onconova Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.02 Insider Own0.30% Shs Outstand236.61M Perf Week-0.76%
Market Cap82.94M Forward P/E- EPS next Y-1.15 Insider Trans177.30% Shs Float221.88M Perf Month-23.22%
Income-24.80M PEG- EPS next Q-0.28 Inst Own23.10% Short Float0.36% Perf Quarter-47.81%
Sales0.20M P/S414.68 EPS this Y90.30% Inst Trans0.08% Short Ratio0.64 Perf Half Y-49.04%
Book/sh2.54 P/B2.04 EPS next Y-71.40% ROA-81.10% Target Price3.05 Perf Year-69.91%
Cash/sh3.00 P/C1.73 EPS next 5Y- ROE-139.30% 52W Range2.85 - 28.95 Perf YTD-25.72%
Dividend- P/FCF- EPS past 5Y- ROI-403.20% 52W High-82.07% Beta1.74
Dividend %- Quick Ratio6.60 Sales past 5Y-54.20% Gross Margin- 52W Low82.01% ATR0.37
Employees11 Current Ratio6.60 Sales Q/Q0.00% Oper. Margin- RSI (14)40.01 Volatility6.25% 7.02%
OptionableYes Debt/Eq0.00 EPS Q/Q32.30% Profit Margin- Rel Volume0.18 Prev Close4.97
ShortableYes LT Debt/Eq0.00 EarningsMay 17 AMC Payout- Avg Volume1.23M Price5.19
Recom2.20 SMA20-6.68% SMA50-20.82% SMA200-44.42% Volume221,516 Change4.43%
May-18-21Initiated Guggenheim Buy $4
Mar-01-18Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18Downgrade Maxim Group Buy → Hold
Oct-09-17Initiated H.C. Wainwright Buy $6
Apr-27-17Initiated Laidlaw Buy $10
Jul-01-15Upgrade Piper Jaffray Neutral → Overweight
May-05-15Initiated H.C. Wainwright Buy $6
Jun-28-21 08:00AM  
Jun-22-21 08:00AM  
Jun-17-21 08:00AM  
Jun-10-21 08:00AM  
Jun-04-21 12:00PM  
Jun-03-21 08:00AM  
Jun-01-21 08:00AM  
May-21-21 08:00AM  
May-20-21 08:32AM  
May-17-21 04:05PM  
May-14-21 10:25AM  
May-10-21 08:00AM  
May-06-21 03:01PM  
Apr-22-21 08:00AM  
Apr-01-21 08:00AM  
Mar-29-21 08:00AM  
Mar-11-21 04:05PM  
Mar-04-21 04:15PM  
Mar-01-21 08:00AM  
Feb-24-21 08:00AM  
Feb-22-21 09:47AM  
Feb-17-21 05:51PM  
Feb-16-21 04:03PM  
Feb-10-21 10:49PM  
Feb-04-21 11:54AM  
Jan-25-21 09:49AM  
Jan-14-21 08:00AM  
Jan-07-21 09:40AM  
Dec-21-20 08:00AM  
Dec-01-20 10:27AM  
Nov-23-20 08:00AM  
Nov-12-20 04:05PM  
Nov-05-20 08:00AM  
Oct-13-20 08:00AM  
Oct-05-20 09:44AM  
Sep-21-20 10:08AM  
Sep-09-20 08:00AM  
Aug-31-20 08:41AM  
Aug-26-20 06:42PM  
Aug-25-20 10:06AM  
Aug-24-20 11:15AM  
Aug-17-20 11:46AM  
Aug-12-20 04:37PM  
Aug-07-20 08:00AM  
Aug-04-20 08:00AM  
Aug-03-20 11:52AM  
Jul-29-20 01:30PM  
Jul-27-20 08:00AM  
Jul-23-20 08:00AM  
Jul-07-20 08:00AM  
Jun-23-20 10:43AM  
Jun-22-20 08:00AM  
Jun-12-20 08:00AM  
Jun-08-20 08:00AM  
May-28-20 09:44AM  
May-18-20 11:33AM  
May-14-20 04:05PM  
May-11-20 08:00AM  
May-07-20 08:00AM  
Apr-27-20 08:00AM  
Apr-07-20 06:40AM  
Apr-02-20 07:00AM  
Mar-24-20 04:05PM  
Mar-18-20 08:00AM  
Mar-13-20 09:46AM  
Mar-02-20 09:54AM  
Feb-21-20 10:12AM  
Feb-20-20 08:45AM  
Feb-19-20 11:19AM  
Feb-18-20 10:06AM  
Feb-10-20 08:00AM  
Feb-04-20 08:00AM  
Jan-23-20 05:44PM  
Jan-03-20 01:27PM  
Jan-02-20 01:48PM  
Dec-31-19 11:30AM  
Dec-23-19 07:33PM  
Dec-19-19 01:44PM  
Dec-18-19 09:05AM  
Dec-17-19 07:30AM  
Dec-10-19 03:07PM  
Dec-09-19 09:00AM  
Dec-07-19 08:35AM  
Dec-06-19 08:49AM  
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLER ABRAHAM N.SVP Corp Dev & Gen CounselFeb 16Buy1.0012,00012,000152,000Feb 17 08:57 AM
Guerin Mark PatrickChief Financial OfficerFeb 16Buy1.0015,00015,000145,213Feb 17 08:55 AM
Fruchtman Steven MPresident, Chief Executive OffFeb 16Buy1.0020,00020,000236,226Feb 17 08:48 AM
MARINO JAMES JDirectorFeb 16Buy1.0025,00025,000230,716Feb 17 08:46 AM
Shoemaker Mary TeresaDirectorFeb 16Buy1.0013,00013,00050,735Feb 17 08:45 AM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselDec 11Buy0.3230,0009,600140,000Dec 14 09:00 AM
Guerin Mark PatrickChief Financial OfficerNov 27Buy0.264,6141,200130,213Nov 30 05:11 PM
Shoemaker Mary TeresaDirectorNov 25Buy0.2737,73510,00037,735Nov 30 05:14 PM
Guerin Mark PatrickChief Financial OfficerNov 25Buy0.2616,7554,356125,599Nov 30 05:11 PM
OLER ABRAHAM N.SVP Corp Dev & Gen CounselNov 25Buy0.2620,0005,120110,000Nov 30 05:09 PM
Fruchtman Steven MPresident, Chief Executive OffNov 25Buy0.2640,00010,360216,226Nov 30 05:08 PM
MARINO JAMES JDirectorNov 24Buy0.2638,77410,004205,716Nov 27 01:34 PM
Reddy E PremkumarDirectorAug 27Sale0.27527,863143,94816,683Aug 31 04:49 PM
Hoffman Michael BDirectorAug 27Sale0.27182,49249,62021,919Aug 31 04:42 PM
Hoffman Michael BDirectorAug 27Sale0.271,8765100Aug 31 04:42 PM